Pam Taub, MD, FACC, FASPC

Articles by Pam Taub, MD, FACC, FASPC

The Cumulative Burden of LDL-C

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 4th 2024

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Overcoming Access Barriers to Novel Non Statin Therapies

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh Patel, MD,Pam Taub, MD, FACC, FASPC

December 21st 2023

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Combination Therapy in LDL Lowering

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 21st 2023

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Nonstatin Agents for LDL-C Lowering

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 14th 2023

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

How Low is Too Low in LDL-C?

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 14th 2023

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Matching the Intensity of Treatment to Cardiovascular Risk

ByC. Michael Gibson, MD,Manesh R. Patel, MD,Payal Kohli, MD, FACC,Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Assessing Cardiovascular Risk in Your Patients

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

Barriers and Solutions for Lipid Management in Clinical Practice

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Multidisciplinary/Team Based Approach for Lipid Management

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 2nd 2022

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Emerging Therapies for Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC

December 2nd 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

The Role of Combination Therapy in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

Managing ASCVD in Patients With Statin Intolerance

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Use of Statins in Management of Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Achievement of LDL-C Goals in the Real World

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

Achievement of Goals in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 28th 2022

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Personalized Treatment for Patients with ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Impact of Lipid Lowering on Risk for ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 21st 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Risk Enhancing Factors in ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

October 14th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

Pam Taub, MD, FACC, FASPC

Articles by Pam Taub, MD, FACC, FASPC

The Cumulative Burden of LDL-C

Overcoming Access Barriers to Novel Non Statin Therapies

Combination Therapy in LDL Lowering

Nonstatin Agents for LDL-C Lowering

How Low is Too Low in LDL-C?

Matching the Intensity of Treatment to Cardiovascular Risk

Assessing Cardiovascular Risk in Your Patients

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

Barriers and Solutions for Lipid Management in Clinical Practice

Multidisciplinary/Team Based Approach for Lipid Management

Emerging Therapies for Hypercholesterolemia

The Role of Combination Therapy in Hypercholesterolemia

Managing ASCVD in Patients With Statin Intolerance

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

Guideline Recommendations for Lipid Lowering

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

Use of Statins in Management of Hypercholesterolemia

Achievement of LDL-C Goals in the Real World

Achievement of Goals in ASCVD

Personalized Treatment for Patients with ASCVD

Impact of Lipid Lowering on Risk for ASCVD

Risk Enhancing Factors in ASCVD

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

Trending on HCPLive

FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years

FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis

Functional Cures for T1D: Insulin Independence Through Islet Transplantation

Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk

The Challenge of Resistant Hypertension